FY2022 EPS Estimates for Vanda Pharmaceuticals Inc. Lifted by Analyst (NASDAQ:VNDA)
FY2022 EPS Estimates for Vanda Pharmaceuticals Inc. Lifted by Analyst (NASDAQ:VNDA)
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Rating) – Analysts at Jefferies Financial Group increased their FY2022 earnings per share estimates for Vanda Pharmaceuticals in a report issued on Monday, August 29th. Jefferies Financial Group analyst C. Howerton now forecasts that the biopharmaceutical company will post earnings of $0.22 per share for the year, up from their previous estimate of $0.18. The consensus estimate for Vanda Pharmaceuticals' current full-year earnings is $0.18 per share. Jefferies Financial Group also issued estimates for Vanda Pharmaceuticals' FY2023 earnings at $0.29 EPS, FY2024 earnings at $0.39 EPS, FY2025 earnings at $0.48 EPS and FY2026 earnings at $0.75 EPS.
万达制药公司(纳斯达克代码:VNDA-GET Rating)-杰富瑞金融集团的分析师在8月29日星期一发布的一份报告中上调了对万达制药2022财年每股收益的预期。杰富瑞金融集团分析师C.Howerton现在预测,这家生物制药公司今年的每股收益将为0.22美元,高于此前预测的0.18美元。对万达制药目前全年收益的普遍估计是每股0.18美元。杰富瑞金融集团还发布了对万达制药2023财年每股收益0.29美元、2024财年每股收益0.39美元、2025财年每股收益0.48美元和2026财年每股收益0.75美元的预期。
Separately, StockNews.com raised Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, June 3rd.
另外,StockNews.com在6月3日周五的一份报告中将万达制药的评级从持有上调至买入。
Vanda Pharmaceuticals Stock Performance
中达医药的股票表现
Insider Transactions at Vanda Pharmaceuticals
万达制药的内幕交易
In other news, CMO Joakim Wijkstrom sold 3,605 shares of the business's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total value of $37,023.35. Following the completion of the transaction, the chief marketing officer now directly owns 96,673 shares of the company's stock, valued at $992,831.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CMO Joakim Wijkstrom sold 3,605 shares of the company's stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total value of $37,023.35. Following the completion of the transaction, the chief marketing officer now directly owns 96,673 shares in the company, valued at $992,831.71. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Stephen Ray Mitchell sold 2,700 shares of the company's stock in a transaction on Monday, June 13th. The shares were sold at an average price of $9.48, for a total value of $25,596.00. Following the completion of the transaction, the director now owns 6,515 shares of the company's stock, valued at $61,762.20. The disclosure for this sale can be found here. Insiders sold a total of 8,544 shares of company stock valued at $87,181 over the last three months. 7.00% of the stock is currently owned by insiders.
在其他新闻方面,CMO Joakim Wijkstrom在8月22日星期一的一次交易中出售了3605股该公司的股票。这只股票的平均售价为10.27美元,总价值为37,023.35美元。交易完成后,首席营销官现在直接持有该公司96,673股股票,价值992,831.71美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过这个超级链接访问。在相关新闻中,CMO Joakim Wijkstrom在8月22日星期一的一次交易中出售了3605股该公司的股票。这只股票的平均售价为10.27美元,总价值为37,023.35美元。交易完成后,首席营销官现在直接持有该公司96,673股股票,价值992,831.71美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过美国证券交易委员会网站访问。此外,董事的斯蒂芬·雷·米切尔在6月13日(星期一)的一次交易中出售了2,700股该公司股票。这些股票的平均价格为9.48美元,总价值为25,596.00美元。交易完成后,董事现在拥有6,515股该公司股票,价值61,762.20美元。此次拍卖的披露信息可在此处找到。在过去的三个月里,内部人士总共出售了8,544股公司股票,价值87,181美元。该公司7.00%的股份目前由内部人士持有。
Hedge Funds Weigh In On Vanda Pharmaceuticals
对冲基金买入万达制药
Institutional investors have recently added to or reduced their stakes in the business. Royce & Associates LP increased its stake in Vanda Pharmaceuticals by 99.2% in the first quarter. Royce & Associates LP now owns 239,627 shares of the biopharmaceutical company's stock valued at $2,710,000 after purchasing an additional 119,329 shares during the last quarter. Citigroup Inc. grew its position in Vanda Pharmaceuticals by 62.7% during the fourth quarter. Citigroup Inc. now owns 151,874 shares of the biopharmaceutical company's stock valued at $2,383,000 after acquiring an additional 58,518 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in Vanda Pharmaceuticals during the first quarter valued at about $119,000. Comerica Bank grew its position in Vanda Pharmaceuticals by 2.5% during the first quarter. Comerica Bank now owns 47,706 shares of the biopharmaceutical company's stock valued at $537,000 after acquiring an additional 1,180 shares during the period. Finally, ProShare Advisors LLC grew its position in Vanda Pharmaceuticals by 6.0% during the fourth quarter. ProShare Advisors LLC now owns 21,558 shares of the biopharmaceutical company's stock valued at $337,000 after acquiring an additional 1,214 shares during the period. 99.42% of the stock is currently owned by institutional investors and hedge funds.
机构投资者最近增持或减持了该公司的股份。Royce&Associates LP在第一季度增持了99.2%的万达制药股份。Royce&Associates LP现在拥有239,627股这家生物制药公司的股票,价值2,710,000美元,在上个季度购买了119,329股。花旗集团(Citigroup Inc.)在第四季度增持了62.7%的万达制药股份。花旗集团(Citigroup Inc.)目前持有这家生物制药公司151,874股股票,价值2,383,000美元,在此期间又购买了58,518股。Campbell&CO Investment Adviser LLC在第一季度购买了Vanda PharmPharmticals的新股份,价值约11.9万美元。Comerica银行在第一季度增持了2.5%的Vanda PharmPharmticals头寸。Comerica银行现在拥有这家生物制药公司47,706股股票,价值537,000美元,在此期间又购买了1,180股。最后,ProShare Advisors LLC在第四季度将其在万达制药的头寸增加了6.0%。ProShare Advisors LLC现在拥有这家生物制药公司21,558股股票,价值337,000美元,在此期间又购买了1,214股。该公司99.42%的股票目前由机构投资者和对冲基金持有。
Vanda Pharmaceuticals Company Profile
万达制药公司简介
(Get Rating)
(获取评级)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
万达制药公司是一家生物制药公司,专注于疗法的开发和商业化,以满足高度未得到满足的医疗需求。该公司的营销产品包括用于治疗非24小时睡眠-觉醒障碍的Hetlioz;以及用于治疗精神分裂症的Fanapt口服药片。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Vanda Pharmaceuticals (VNDA)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
- 免费获取StockNews.com关于万达制药的研究报告(VNDA)
- 耐克股票会被超卖,但仍被高估吗?
- 美国铝业是在第二季度业绩强劲和更多股票回购之后买入的吗?
- 皇家加勒比的宽带合作能否推动收入增长?
- 芯片设备制造商Entigis很有潜力,但它现在可以买下吗?
- DocuSign在报告收益时有重要的问题需要解决
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Vanda PharmPharmticals Daily》新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vanda PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。